Local screening coordinator praises sickle cell and thalassaemia genetic risk and counselling course. Bursaries are available for the next course in 2018.
We have updated our national guidance on counselling and referral for prenatal diagnosis for women and couples at risk of having a baby with sickle cell disease or thalassaemia major.
Early access to sickle cell and thalassaemia screening and the early offer of prenatal diagnosis (PND) is important in giving women and couples time to consider their options.
We’re pleased to announce the publication of an updated version of the antenatal laboratory handbook for the NHS Sickle Cell and Thalassaemia (SCT) Screening Programme.
This study day is for non specialist nurses, midwives and health visitors working in SCT screening in England. Accredited by the Royal College of Midwives, I am pleased to say we are able to provide funding for eligible participants.
As part of a wider investigation into why women are tested late, we commissioned the UK Thalassaemia Society (UKTS) and Sickle Cell Society (SCS) to carry out face to face interviews with women and couples who had recent experience of the SCT programme.
I’m the Sickle Cell and Thalassaemia Screening Lead at Northampton General Hospital and Kettering General Hospital. For the past year I’ve been on secondment as national project lead for the NHS Sickle Cell and Thalassaemia (SCT) Screening Programme.
We’ve now published the screening key performance indicator (KPI) data for the fourth quarter of 2016 to 2017 (Q4, January to March 2017). The KPIs are used to measure how NHS screening programmes are performing and aim to give a high level overview of programme quality.
Related content and links
The PHE Screening team
Public Health England (PHE) existed to protect and improve the nation’s health and wellbeing, and reduce health inequalities. It closed on 30 September 2021 and this blog is no longer updated.
